Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

Author： Doggrell Sheila A Christensen Anne-Marie

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.1, 2011-01, pp. : 157-163

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona Martinelli Giovanni Rosti Gianantonio Iacobucci Ilaria Baccarani Michele

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite

New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

Current Medicinal Chemistry, Vol. 17, Iss. 13, 2010-05 ,pp. : 1220-1245

Bentham Science Publishers

Access to resources Recommend Favorite

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

By O'Hare Thomas Eide Christopher A Deininger Michael W

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 865-878

Informa Healthcare

Access to resources Recommend Favorite

BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile

Current Medicinal Chemistry, Vol. 18, Iss. 19, 2011-06 ,pp. : 2943-2959

Bentham Science Publishers

Access to resources Recommend Favorite

BCR-ABL mutations and resistance to imatinib mesylate in Ph+ leukaemia

Inpharma, Vol. 1, Iss. 1325, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite